SALVAGE CHEMOTHERAPY WITH ABVD IN MOPP-RESISTANT HODGKINS-DISEASE
SALVAGE CHEMOTHERAPY WITH ABVD IN MOPP-RESISTANT HODGKINS-DISEASE
复制标题
DOI：
10.7326/0003-4819-96-2-139
复制
发表时间：
1982-01-01
影响因子：
39.2
通讯作者：
BONADONNA, G
中科院分区：
文献类型：
--
作者：
SANTORO, A;BONFANTE, V;BONADONNA, G
连续 55 名对 MOPP 化疗（氮芥、长春新碱、丙卡巴肼和泼尼松）耐药的晚期复发性霍奇金病患者接受 ABVD 化疗（多柔比星、博莱霉素、长春花碱和达卡巴嗪）。在 54 名可评估疗效的患者中，59% 的患者在病理再分期后完全缓解，13% 的患者部分缓解。在主要 MOPP 治疗期间出现疾病进展的 29 名患者中有 15 名 (52%) 在 ABVD 后达到完全缓解。完成反应的中位时间为 3 个月。完全缓解的中位持续时间为 17 个月； 38% 获得完全缓解的患者在开始 ABVD 治疗后 5 年内仍存活且持续无病。完全缓解者的中位生存期超过 60 个月。除了 1/2 的患者出现明显呕吐外，毒性表现中等。 ABVD 显然是 MOPP 耐药性霍奇金病的有效挽救方案。
Fifty-five consecutive patients with advanced recurrent Hodgkin''s disease resistant to MOPP chemotherapy (mechlorethamine, vincristine, procarbazine and prednisone) were given ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine). In 54 patients evaluable for response, complete remission after pathologic restaging was seen in 59% and partial remission in 13%. Fifteen of 29 patients (52%) showing disease progression during primary MOPP treatment achieved complete remission after ABVD. The median time to complete response was 3 mo. The median duration for complete remission was 17 mo.; 38% of patients who attained complete remission have remained alive and continuously disease free at 5 yr from start of ABVD treatment. The median survival of complete responders was more than 60 mo. Toxic manifestations were moderate, aside from pronounced vomiting in 1/2 of patients. ABVD evidently is an effective salvage regimen for MOPP-resistant Hodgkin''s disease.